XML 97 R86.htm IDEA: XBRL DOCUMENT v3.24.3
Collaboration and Licensing Agreements (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Sep. 30, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Prepaid expenses and other current assets $ 1,627.0 $ 2,028.1 $ 1,627.0
Variable Interest Entity, Not Primary Beneficiary | Mapi Pharma Ltd.      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Variable Interest Entity, Maximum Milestone Payments 90.0   90.0
Variable Interest Entity, Financial or Other Support, Amount   $ 30.0  
Equity Securities, FV-NI, Unrealized Gain (Loss) 45.6    
Other Assets 132.1   132.1
Gain (Loss) on Investments     62.1
Prepaid expenses and other current assets $ 52.5   52.5
Collaborative Arrangement | Mapi Pharma Ltd.      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Payments to Acquire in Process Research and Development     75.0
Maximum      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Development and sales milestone payments     412.0
Maximum | Collaborative Arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Development and sales milestone payments     $ 8.0